In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration

被引:55
|
作者
Fang, Min
Jin, Yilin
Bao, Wei
Gao, Hui
Xu, Mengjin
Wang, Di
Wang, Xia
Yao, Ping
Liu, Liegang [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Nutr & Food Hyg, Hubei Key Lab Food Nutr & Safety, Tongji Med Coll,Sch Publ Hlth, Wuhan 430030, Peoples R China
来源
基金
中国国家自然科学基金; 国家高技术研究发展计划(863计划);
关键词
curcumin; oral bioavailability; tissue distribution; ANTIOXIDANT ACTIVITY; TISSUE DISTRIBUTION; TURMERIC OIL; NANOPARTICLES; PHARMACOKINETICS; LONGA; FORMULATION; DELIVERY; SYSTEM; MODEL;
D O I
10.2147/IJN.S36257
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: Curcumin has a variety of pharmacological effects. However, poor water solubility and low oral bioavailability limit its clinical utility. A delivery system for nanostructured lipid carriers has been reported to be a promising approach to enhancing the oral absorption of curcumin. The aim of the present study was to investigate the pharmacokinetics, tissue distribution, and relative bioavailability of curcumin in rats after a single intragastric dose of a nanostructured lipid curcumin carrier formulation. Methods: Nanostructured lipid curcumin carriers were prepared using the ethanol dripping method and characterized in terms of the particle size, polydispersity index, zeta potential, differential scanning calorimetry, drug-loading capacity, encapsulation efficiency, and in vitro release. The pharmacokinetics and tissue distribution of nanostructured lipid curcumin carriers and curcumin suspension were compared after intragastric administration. Results: Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 +/- 14.98 ng/mL versus 279.43 +/- 7.21 ng/mL, P<0.01), a shorter time taken to reach peak plasma concentration (0.5 +/- 0.01 hour versus 1.0 +/- 0.12 hour, P. 0.01), and a greater AUC(0-infinity) (820.36 +/- 25.11 mg x hour/L versus 344.11 +/- 10.01 mg x hour/L, P < 0.05) compared with curcumin suspension. In the tissue distribution studies, curcumin could be detected in the spleen, heart, liver, kidneys, lungs, and brain. Following intragastric administration of the nanostructured lipid curcumin carrier formulation, tissue concentrations of curcumin also increased, especially in the brain. The nanostructured lipid curcumin carrier formulation improved the ability of curcumin to cross the blood-brain barrier, with an 11.93-fold increase in the area under the curve achieved in the brain when compared with curcumin suspension. Conclusion: The nanostructured lipid carrier formulation significantly improved the oral bioavailability of curcumin and represents a promising method for its oral delivery.
引用
收藏
页码:5395 / 5404
页数:10
相关论文
共 50 条
  • [21] Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation
    Polat, Heybet Kerem
    Kurt, Nihat
    Aytekin, Eren
    cayli, Yagmur Akdag
    Pehlivan, SibelBozdag
    calis, Sema
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 38 (06) : 412 - 423
  • [22] Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation
    Li, Min
    Pei, Jianying
    Ma, Zhenzhen
    Fu, Juntao
    Chen, Feifan
    Du, Shuzhang
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 731 - 739
  • [23] Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis
    Khan, Anam Sajjad
    Din, Fakhar Ud
    Ali, Zakir
    Bibi, Maryam
    Zahid, Fatima
    Zeb, Alam
    Mujeeb-Ur-Rehman
    Khan, Gul Majid
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 593
  • [24] Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC):: In vitro and in vivo studies
    Ricci, M
    Puglia, C
    Bonina, F
    Di Giovanni, C
    Giovagnoli, S
    Rossi, C
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (05) : 1149 - 1159
  • [25] Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation
    Min Li
    Jianying Pei
    Zhenzhen Ma
    Juntao Fu
    Feifan Chen
    Shuzhang Du
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 85 : 731 - 739
  • [26] Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
    Doktorovova, Slavomira
    Kovacevic, Andjelka B.
    Garcia, Maria L.
    Souto, Eliana B.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2016, 108 : 235 - 252
  • [27] Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: Design, characterization and in vivo evaluation
    Han, Fei
    Yin, Ran
    Che, Xin
    Yuan, Jing
    Cui, Yanan
    Yin, He
    Li, Sanming
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 439 (1-2) : 349 - 357
  • [28] Curcumin and Genistein Coloaded Nanostructured Lipid Carriers: in Vitro Digestion and Antiprostate Cancer Activity
    Aditya, N. P.
    Shim, Myeongkuk
    Lee, Inae
    Lee, YoungJoo
    Im, Moo-Hyeog
    Ko, Sanghoon
    [J]. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2013, 61 (08) : 1878 - 1883
  • [29] Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy
    Cirri, Marzia
    Maestrini, Lavinia
    Maestrelli, Francesca
    Mennini, Natascia
    Mura, Paola
    Ghelardini, Carla
    Mannelli, Lorenzo Di Cesare
    [J]. DRUG DELIVERY, 2018, 25 (01) : 1910 - 1921
  • [30] Experimental validation of biocompatible nanostructured lipid carriers of sophorolipid: Optimization, characterization and in-vitro evaluation
    Kanwar, Rohini
    Gradzielski, Michael
    Prevost, Sylvain
    Appavou, Marie-Sousai
    Mehta, S. K.
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 2019, 181 : 845 - 855